Becton Dickinson & Co Stock Price, News & Analysis

BD (NYSE:BDX) announced a pharmacy automation partnership with Henry Ford Health on Sept. 22, 2025 to develop a hospital and community pharmacy robotic solution using the BD Rowa Vmax.

The collaboration will pilot 24/7 prescription pickup, automated high-capacity storage and refrigerated handling, real-time prescription tracking, and modular scalability to improve pharmacy staff efficiency and ensure patients leave with medications in hand at discharge or clinic visits.

BD (NYSE: BDX) announced the appointment of Robert Huffines and Jacqueline Wright to its board of directors, effective Dec. 1, 2025. The company said the additions add expertise in health care, technology, digital transformation, artificial intelligence, finance and capital markets as BD advances its strategy to be a scaled pure‑play medical technology company. BD added three new independent directors in 2025, reflecting ongoing board refreshment. Bios note Huffines' 30+ years in healthcare investment banking and board service, and Wright's 30+ years in technology and digital transformation at McKinsey and Microsoft.

BD (NYSE: BDX) announced that the CE-marked BD Onclarity HPV Assay for the BD COR and BD Viper LT systems received WHO prequalification on November 17, 2025, enabling wider use in low- and middle-income countries.

The assay detects 14 high-risk HPV types with extended genotyping (six individual types plus three genotype groups), supports self-collection including at-home where CE is recognized, and targets improved risk stratification and follow-up. The BD COR offers ~1,650-test capacity and up to 1,000 results in 24 hours; BD Viper LT provides compact, decentralized molecular testing.

BD (NYSE: BDX) announced on November 13, 2025 that Duncan Regional Hospital is the first U.S. hospital to go live with BD Alaris™ EMR Infusion Interoperability integrated with MEDITECH. The integration enables bi-directional communication between MEDITECH and Alaris infusion pumps, allowing clinicians to scan to verify patients, medications and pumps; send infusion orders from MEDITECH to pumps; and receive infusion status back into the EHR.

The rollout expands BD's market-leading interoperability—now live at more than 960 U.S. sites—to all three leading U.S. EHRs, and BD reports a pace of about 12 new site activations per month.

BD (NYSE: BDX) on Nov 12, 2025 introduced the PureWick™ Portable Collection System, a battery-powered, non-invasive urine management device designed for wheelchair users and mobile use.

Key facts: the device offers up to 8 hours battery life, is mountable or carriable, compatible with PureWick™ male and female external catheters, and is sold via PureWickAtHome.com and phone ordering. The PureWick portfolio has sold > 55 million external catheters and is used in > 4,500 hospitals and rehab facilities in the U.S.; a survey of 150 users/caregivers found > 90% would recommend the PureWick urine collection system. BD positions the portable unit to improve mobility, discretion, and skin protection for people managing urinary incontinence.

BD (NYSE: BDX) reported fiscal 2025 Q4 revenue of $5.9B (+8.3% reported, +7.0% FXN, +3.9% organic) and fiscal 2025 revenue of $21.8B (+8.2% reported, +7.7% FXN, +2.9% organic).

Q4 GAAP diluted EPS was $1.72 and adjusted diluted EPS was $3.96. Full-year GAAP EPS was $5.82 (down 0.7%) and adjusted diluted EPS was $14.40 (+9.6%). Adjusted operating margin improved to 25.0%; GAAP operating margin was 11.8%.

BD returned $2.2B to shareholders in FY25 and provided FY26 guidance of low single-digit revenue growth and adjusted diluted EPS of $14.75–$15.05. Management reiterated the planned combination of Biosciences and Diagnostic Solutions with Waters around end of Q1 CY2026.

BD (NYSE: BDX) declared a quarterly dividend of $1.05 per share, a 1.0% increase from the prior quarter. The dividend is payable on December 31, 2025 to holders of record on December 8, 2025.

The company set an indicated annual dividend rate for fiscal year 2026 of $4.20 per share. This marks the 54th consecutive fiscal year BD has raised its dividend, maintaining its membership in the S&P 500 Dividend Aristocrats Index. Management linked the increase to confidence in BD's long-term outlook during execution of the Waters RMT transaction.

BD (NYSE: BDX) announced on November 4, 2025 that the AGILITY IDE study has achieved full enrollment of the common and external iliac artery cohort (n=118) for the Revello™ Vascular Covered Stent in peripheral artery disease (PAD).

The multi-center, prospective AGILITY study (NCT06111469) is enrolling at up to 45 sites across the United States, Europe, Australia and New Zealand and includes a second cohort for superficial femoral and proximal popliteal arteries (n=223) with enrollment ongoing. The milestone was announced during a late-breaking presentation at VIVA 2025 by Dr. Sean Lyden.

BD (NYSE: BDX) received FDA 510(k) clearance and CE-IVDR/CE marking for its Enteric Bacterial Panel (EBP) and Enteric Bacterial Panel plus (EBP plus) for the BD COR™ System on Nov 3, 2025.

The molecular panels use PCR on the BD COR system to detect a broad range of GI bacterial pathogens from a single stool swab and run on a high-throughput automated system with capacity for nearly 1,650 tests and up to 1,000 sample results in 24 hours, plus up to 7 hours walk-away time and room-temperature reagents.